Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review-Reference-Cited by-同舟云学术

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review

Published:2023-01 Issue: Volume:22 Page:153303382311735
ISSN:1533-0346
Container-title:Technology in Cancer Research & Treatment
language:en
Short-container-title:Technol Cancer Res Treat

Author:

Wang Wei¹²,Wu Jiayi¹³,Chen Keyu¹³^ORCID,Wang Xiaojia¹^ORCID,Shao Xiying¹

Affiliation:

1. Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, People's Republic of China

2. Department of Clinical Medicine, Wenzhou Medical University, Wenzhou, People's Republic of China

3. Department of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China

Abstract

Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/15330338231173504

Reference40 articles.

1. Cancer statistics, 2022

2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

3. Palbociclib and Letrozole in Advanced Breast Cancer

4. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

5. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast;Molecular Biology Reports;2024-02-23